REZOLUTE INC (RZLT) Stock News

USA - NASDAQ:RZLT - US76200L3096 - Common Stock

9.19 USD

+0.17 (+1.88%)

Last: 10/24/2025, 8:00:01 PM

9.19 USD

0 (0%)

After Hours: 10/24/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RZLT Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Rezolute, Inc.

Rezolute to Participate in Upcoming Investor Conferences

17 days ago - By: Rezolute, Inc.

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 days ago - By: Rezolute, Inc.

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 days ago - By: Benzinga - Mentions: ABT BSX LLY PFE ...

10 Health Care Stocks Whale Activity In Today's Session

a month ago - By: Rezolute, Inc.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

a month ago - By: Rezolute, Inc.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

2 months ago - By: Rezolute, Inc.

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

2 months ago - By: Rezolute, Inc.

Rezolute to Participate in Upcoming Investor Conferences

2 months ago - By: Rezolute, Inc.

Rezolute to Participate in Upcoming Investor Conferences

2 months ago - By: Rezolute, Inc.

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

2 months ago - By: Rezolute, Inc.

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

2 months ago - By: Benzinga - Mentions: CLDX BMY HUM TEM ...

10 Health Care Stocks Whale Activity In Today's Session

3 months ago - By: Rezolute, Inc.

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

3 months ago - By: Rezolute, Inc.

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

4 months ago - By: Rezolute, Inc.

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

4 months ago - By: Rezolute, Inc.

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

5 months ago - By: Rezolute, Inc.

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

5 months ago - By: Yahoo Finance - Mentions: DHI CMG F

Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential

5 months ago - By: Yahoo Finance - Mentions: SPTN HD HLIT IDCC ...

Number Sense: Will retail define SpartanNash’s future?

6 months ago - By: Rezolute, Inc.

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

6 months ago - By: Rezolute, Inc.

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

6 months ago - By: Rezolute, Inc.

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

6 months ago - By: Rezolute, Inc.

Rezolute to Participate in Upcoming Investor Conferences

6 months ago - By: Rezolute, Inc.

Rezolute to Participate in Upcoming Investor Conferences

6 months ago - By: Rezolute, Inc.

Rezolute, Inc. Announces Closing of Underwritten Offering

6 months ago - By: Rezolute, Inc.

Rezolute, Inc. Announces Closing of Underwritten Offering

6 months ago - By: Rezolute, Inc.

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

6 months ago - By: Rezolute, Inc.

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

6 months ago - By: Rezolute, Inc.

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

7 months ago - By: Rezolute, Inc.

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

7 months ago - By: Rezolute, Inc.

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors